The research team, led by Wenjing Wang and colleagues, searched PubMed, Scopus, and Web of Science for studies published since 2014, applying the rigorous standards of the PRISMA reporting framework and registering the protocol prospectively with PROSPERO under registration number CRD42025648170. Their aim was deceptively simple but methodologically demanding: to estimate pooled incidence and prevalence of urinary tract infections across different healthcare settings, and then to dissect those estimates by geography, infection setting, and host risk profile. The final dataset included 969,476 participants, a scale that lends considerable statistical weight to the pooled estimates.

The headline finding concerns the stark divide between hospital-acquired and community-acquired infections. Hospital-acquired urinary tract infections, abbreviated HAUTIs in the study, showed a pooled incidence proportion of 0.17, with a 95 percent confidence interval of 0.13 to 0.22, and a pooled prevalence of 0.21, with a confidence interval of 0.16 to 0.25. By comparison, community-acquired urinary tract infections showed a pooled incidence of just 0.08, with a confidence interval of 0.06 to 0.10. In practical terms, roughly one in five hospitalised patients in the included studies had or acquired a urinary tract infection, a figure that underscores how the hospital environment itself, with its invasive devices, immunocompromised patients, and dense microbial ecology, amplifies infection risk.

Within the hospital setting, the single most dangerous factor identified was the urinary catheter. Catheter-associated urinary tract infections emerged as a particularly high-risk category, which is consistent with the well-understood biology of these devices. An indwelling catheter provides bacteria with a direct conduit into the bladder, bypassing the natural flushing action of urination and forming a biofilm on its surface that shields microbes from both immune defences and antibiotics. The meta-analysis confirms that this device-related pathway remains a dominant driver of nosocomial urinary infection, and that catheter stewardship, meaning the avoidance, early removal, and meticulous management of urinary catheters, must sit at the centre of any prevention strategy.

Geography mattered as much as setting. The burden of hospital-acquired urinary tract infections was highest in Asia, Africa, and South America, a pattern that likely reflects a combination of factors including differences in healthcare infrastructure, catheterisation practices, antibiotic access, and surveillance capacity across regions. The authors argue that this regional variation exposes a central weakness in current infection control thinking: a uniform, one-size-fits-all prevention approach cannot adequately serve settings whose baseline risks, resources, and microbial ecologies differ so dramatically. Tailored protocols calibrated to local epidemiology, they suggest, are the realistic path forward.

On the microbiological front, the analysis confirmed what clinical microbiologists have long observed: gram-negative bacteria, and particularly Escherichia coli, dominate the etiology of urinary tract infections. Escherichia coli’s specialised adaptations for the urinary tract, including adhesive pili that bind to bladder epithelial cells and an ability to persist intracellularly, make it an exceptionally effective uropathogen. The predominance of gram-negative organisms carries practical consequences, because rising antimicrobial resistance in this bacterial group, particularly extended-spectrum beta-lactamase production, increasingly constrains empiric treatment choices in many regions.

Beyond setting and geography, the study systematically catalogued host-level risk factors, identifying gender, age, comorbidities, and prior disease history as consistent predictors of infection. Some of the most striking quantitative results came from specific vulnerable populations. Among kidney transplant recipients, those who experienced delayed graft function, a complication in which the transplanted kidney does not immediately work properly, faced a risk ratio of 1.63 for urinary tract infection, with a confidence interval of 1.19 to 2.22. This makes biological sense: impaired graft function alters urinary flow and immune regulation, and transplant patients are simultaneously subjected to immunosuppressive drugs that blunt their defences against bacterial invasion.

Pregnant women formed another clearly delineated high-risk group. The analysis found that lower educational attainment among pregnant women was associated with an elevated risk of urinary tract infection, with a pooled effect estimate of 0.40 and a confidence interval of 0.16 to 0.63. Pregnancy itself predisposes to urinary infection through hormonal relaxation of the ureters and mechanical compression of the urinary tract by the growing uterus, which slows urine flow and allows bacteria more time to establish themselves. Untreated infections in pregnancy can escalate to pyelonephritis and are associated with adverse outcomes for both mother and fetus, which is why identifying modifiable social determinants of risk, such as access to health education, carries real public health value.

The study also highlighted the elderly and people with diabetes as key vulnerable groups. Diabetes impairs immune function and, when poorly controlled, glycosuria creates a nutrient-rich environment in the urine that favours bacterial growth. Ageing, meanwhile, brings anatomical and physiological changes, incomplete bladder emptying, and higher rates of catheterisation and institutional care, all of which compound infection risk. By quantifying these risks within a single analytical framework, the review provides clinicians and policymakers with a stratified map of exactly where preventive effort should be concentrated, rather than spreading resources thinly across the entire patient population.

The broader significance of this work lies in its framing. Rather than treating urinary tract infections as a single homogeneous disease, the authors demonstrate that the burden is sharply stratified by where a patient is treated and who the patient is. That insight supports the development of risk-stratified infection control protocols: aggressive catheter reduction programmes and surveillance in hospitals, targeted screening and education for pregnant women, heightened vigilance in transplant units, and tailored prevention for diabetic and elderly patients. As antimicrobial resistance narrows the treatment options available for gram-negative uropathogens, preventing infections in the first place becomes not merely a convenience but a necessity. This meta-analysis, synthesising evidence from nearly a million people across continents and care settings, offers the clearest evidence yet of where that prevention effort must be aimed.

Subject of Research: Global epidemiology and risk-stratified burden of urinary tract infections across healthcare settings and high-risk populations

Article Title: Risk-stratified epidemiology and global burden of urinary tract infections across healthcare and high-risk populations: a systematic review and meta-analysis

Article References: Wang, W., Huo, N., Ma, H., Li, X., & Wang, Y. (2026). Risk-stratified epidemiology and global burden of urinary tract infections across healthcare and high-risk populations: a systematic review and meta-analysis. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14395-z

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14395-z

Keywords: urinary tract infection, hospital-acquired infection, catheter-associated UTI, meta-analysis, Escherichia coli, kidney transplant, pregnancy, diabetes, infection control, antimicrobial resistance, global health burden, risk factors

The new research, conducted at Rabin Medical Center, the largest solid organ transplant center in Israel, and published in Archives of Osteoporosis, followed 39 adults who received teriparatide, a recombinant analogue of human parathyroid hormone, after kidney, lung, or liver transplantation. The investigators report that patients treated with the drug for a median of more than 22 months gained significant bone mineral density at the lumbar spine, femoral neck, and total hip, while clinicians observed acceptable metabolic safety and no episodes of graft rejection during therapy. The findings offer some of the most detailed evidence to date on anabolic osteoporosis treatment in a population that has long been underrepresented in bone research.

The scale of the skeletal problem after transplantation is difficult to overstate. In this cohort, 90 percent of patients had already suffered at least one fragility fracture before starting teriparatide, and 79 percent had multiple broken bones. The immune-suppressing glucocorticoids that nearly all transplant recipients take, at an average dose of around 7 milligrams of prednisone-equivalent per day in this study, directly impair the bone-forming cells called osteoblasts while accelerating bone resorption. Combined with pre-existing organ dysfunction, vitamin D deficiency, and the metabolic upheaval of end-stage organ disease, the result is a skeleton under relentless attack in patients who often cannot tolerate standard therapies.

Teriparatide works differently from the antiresorptive drugs, such as bisphosphonates, that are usually the first line of defense against post-transplant bone loss. Rather than slowing bone breakdown, it stimulates new bone formation by mimicking intermittent pulses of parathyroid hormone, a signal that activates osteoblasts when delivered in daily injections. This anabolic mechanism has made it a first-line option for severe glucocorticoid-induced osteoporosis in the general population. But transplant medicine has harbored a persistent worry: laboratory and clinical studies have suggested that bones in chronic kidney disease and after transplantation may become resistant to parathyroid hormone signaling, a condition linked to adynamic bone disease in which the cellular machinery for building bone falls silent. Skeptics questioned whether an anabolic drug could overcome that resistance.

The new data argue that, in many patients, it can. Among the subset of participants with paired bone density scans taken at the start and end of therapy, lumbar spine bone mineral density rose by an average of 11 percent, femoral neck density by 8 percent, and total hip density by 11 percent, gains that the authors note are comparable to responses reported in non-transplant populations and exceed what antiresorptive drugs typically achieve in transplant recipients. Statistically, the increases reached significance at all three skeletal sites. Treatment was started a median of 36 months after transplantation, once graft function and immunosuppressive regimens had often stabilized, and continued for a median of 22.3 months, a longer exposure than in most previous reports.

Fracture outcomes, though limited by small numbers, added a reassuring note. Six patients broke bones after starting teriparatide, but only two of those fractures occurred while the drug was actively being taken; the other four happened months to years after treatment had stopped. Given that nearly every participant entered the study with an already shattered fracture history, the apparent stabilization of fracture incidence during therapy is clinically meaningful, even though the retrospective design and small sample size prevented the study from formally demonstrating fracture reduction.

Safety, particularly for the transplanted organ itself, was a central question. Kidney function, measured by estimated glomerular filtration rate, declined modestly during the first six months of therapy, from an average of 73 to 64 milliliters per minute per 1.73 square meters, and then stabilized through the remainder of treatment and follow-up. Crucially, a contemporaneous matched group of transplant recipients who never took teriparatide showed a broadly similar decline over the same period, suggesting the change reflected the natural course of post-transplant kidney function rather than a drug effect. No patient progressed to end-stage kidney disease or required dialysis, and metabolic complications were rare: a single case of hypercalcemia, which resolved when the drug was stopped, and no cases of significant hypercalciuria despite most patients taking calcium and vitamin D supplements.

The study’s authors are careful to frame these results within the limits of a single-center, retrospective design. Patients were not randomly assigned; teriparatide was reserved for those with the most severe disease, often after failure of or intolerance to bisphosphonates, a selection reinforced by national reimbursement criteria in Israel. The matched control group was used only to contextualize kidney function trends, not to compare treatment effects, and causality cannot be inferred. Yet the very severity of the treated cohort strengthens the clinical signal: these were patients whose skeletons had already failed, and they still built substantial new bone. Only one randomized trial has previously tested teriparatide after transplantation, a short six-month study in kidney recipients begun during the intense immunosuppression of early recovery, which found no density gains but did prevent bone loss compared with placebo.

By including lung and liver recipients alongside kidney patients, the new study extends the evidence base to populations for which no dedicated osteoporosis treatment guidelines exist, in contrast to the organ-specific guidelines published for heart, kidney, and liver transplant care. The results align with recent observational work showing that teriparatide outperformed alendronate in renal transplant recipients and produced meaningful density gains in patients with low bone turnover, and they add histological and clinical weight to case reports of improved bone formation in heart transplant patients. Taken together, the picture emerging is that skeletal resistance to parathyroid hormone after transplantation, while a real phenomenon, is not an insurmountable barrier when therapy is timed after graft stabilization and sustained for nearly two years.

For clinicians, the message is one of selective optimism rather than blanket prescription. Teriparatide is expensive, requires daily injections, and carries a limited treatment duration, so it is unlikely to become a universal post-transplant remedy. But for the growing population of transplant survivors with severe osteoporosis, prior fractures, and few remaining options, the study suggests a viable path: an anabolic window that can rebuild what immunosuppression has torn down, administered with routine monitoring of calcium and kidney function. The authors call for prospective trials to define the optimal timing, duration, and sequencing of anabolic therapy after transplantation, questions that will only grow more urgent as transplant medicine continues to extend survival and shifts its focus toward the long-term quality of the lives it saves.

Subject of Research: Teriparatide treatment of severe osteoporosis in solid organ transplant recipients

Article Title: Teriparatide treatment of osteoporosis in solid organ transplant recipients—a single-center experience

Article References: Diker Cohen, T., Shraga-Slutzky, I., Kaminer, K., Gorshtein, A., Dotan, I., & Tsvetov, G. (2026). Teriparatide treatment of osteoporosis in solid organ transplant recipients—a single-center experience. Archives of Osteoporosis, 21(1), Article 136. https://doi.org/10.1007/s11657-026-01751-4

Image Credits: AI Generated

DOI: 10.1007/s11657-026-01751-4

Keywords: teriparatide, osteoporosis, solid organ transplantation, bone mineral density, fragility fractures, glucocorticoid-induced osteoporosis, anabolic therapy, kidney transplant, lung transplant, liver transplant, kidney function, transplant immunosuppression